reports
- David Nierengarten
- Dennis Pak
- Martin Fan
- Yun Zhong
Wave Life Sciences Reports Second Quarter 2025 Financial Results and P...
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 ...
- Wedbush Research
- Yun Zhong
AATD Multi-Dose Data Should Be Good; Could Be Available Soon
Initial INHBE data in 2H25 Will be the Next Catalyst. WVE expects to report safety and tolerability, as well as biomarker data that could reflect healthy weight loss from the placebo-controlled study (NCT06842186). We would expect positive stock reaction if the data show dose-dependent knockdown of
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for...
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company’s second quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wa...
- Abe Rimatzki
- Seth Basham
TSLA TESLA INC
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
KURA KURA ONCOLOGY INC.
BLDR BUILDERS FIRSTSOURCE INC.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
AAPL APPLE INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
RBLX ROBLOX
ATXS ASTRIA THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
SOUN SOUNDHOUND AI INC
NATL NCR ATLEOS CORPORATION
- Wedbush Research
- Yun Zhong
Wave Life Sciences Announces Oral Presentation of Preclinical Data Sup...
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with st...
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conf...
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2025 Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 4:55 p.m. ET. A live webcast of this presentation can be acce...
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as ...
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical development of Wave’s robust RNA medicines pipeline CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave’s e...
- Wedbush Research
SHAK SHAKE SHACK INC. CLASS A
DEI DOUGLAS EMMETT INC
HPP HUDSON PACIFIC PROPERTIES INC.
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TXRH TEXAS ROADHOUSE INC.
TSLA TESLA INC
TRNO TERRENO REALTY CORPORATION
STKS ONE GROUP HOSPITALITY
STAG STAG INDUSTRIAL INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBUX STARBUCKS CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PEGA PEGASYSTEMS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
MCD MCDONALD'S CORPORATION
JACK JACK IN THE BOX INC.
IMAX IMAX CORPORATION
EGP EASTGROUP PROPERTIES INC.
EAT BRINKER INTERNATIONAL INC.
DIN DINE BRANDS GLOBAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
BXP BOSTON PROPERTIES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
BJRI BJ'S RESTAURANTS INC.
FRX_CN FENNEC PHARMACEUTICALS
CMG CHIPOTLE MEXICAN GRILL INC.
DRI DARDEN RESTAURANTS INC.
WVE WAVE LIFE SCIENCES
PLYM PLYMOUTH INDUSTRIAL REIT INC.
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
YMAB Y-MABS THERAPEUTICS
TVTX TRAVERE THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
TNGX TANGO THERAPEUTICS
VERA INC
BROS VERA THERAPEUTICS INC
STRW DUTCH BROS INC
CAVA STRAWBERRY FIELDS REIT INC.
JBIO CAVA GROUP INC
JADE BIOSCIENCES
INC.
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
VYGR VOYAGER THERAPEUTICS INC.
CTMX CYTOMX THERAPEUTICS INC.
FRX_CN FENNEC PHARMACEUTICALS
WVE WAVE LIFE SCIENCES
MRSN MERSANA THERAPEUTICS
ISR ISORAY
RCKT ROCKET PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
YMAB Y-MABS THERAPEUTICS
TNGX TANGO THERAPEUTICS
INC
- Yun Zhong
Wave Life Sciences Reports First Quarter 2025 Financial Results and Pr...
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort ...
- Wedbush Research
UDR UDR INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
GERN GERON CORP.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
CPT CAMDEN PROPERTY TRUST
CNK CINEMARK HOLDINGS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AVB AVALONBAY COMMUNITIES INC.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
VICI VICI PROPERTIES INC
APLS APELLIS PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
RCUS ARCUS BIOSCIENCES
PEAK HEALTHPEAK PROPERTIES INC.
RVMD REVOLUTION MEDICINES
CRSR CORSAIR GAMING
PRAX PRAXIS PRECISION MEDICINES
FUBO FUBOTV
RKT ROCKET COMPANIES
CSR CENTERSPACE
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
NTST NETSTREIT CORP
VIGL VIGIL NEUROSCIENCE INC
HR HEALTHCARE TRUST OF AMERICA INC.
SYRE SPYRE THERAPEUTICS INC.
BNL BROADSTONE NET LEASE INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
RARE ULTRAGENYX PHARMACEUTICAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
GERN GERON CORP.
BCRX BIOCRYST PHARMACEUTICALS INC.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
RVMD REVOLUTION MEDICINES
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for ...
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company’s first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.